ALPHAHELIX MOL.DIAGN. SK1 (4MB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ALPHAHELIX MOL.DIAGN. SK1 (4MB) has a cash flow conversion efficiency ratio of -2.585x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-1.21 Million ≈ $-1.41 Million USD) by net assets (€468.00K ≈ $547.14K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 4MB days of operational coverage to measure how many days the company can operate on defensive assets alone.
ALPHAHELIX MOL.DIAGN. SK1 - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how ALPHAHELIX MOL.DIAGN. SK1's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ALPHAHELIX MOL.DIAGN. SK1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ALPHAHELIX MOL.DIAGN. SK1 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
The Alumasc Group plc
LSE:ALU
|
0.068x |
|
VULTUS AB
F:V06
|
0.733x |
|
Grupo Famsa S.A.B. de C.V
MX:GFAMSAA
|
0.002x |
|
Identillect Technologies Corp
V:ID
|
0.006x |
|
Asian Television Network International Ltd
V:SAT
|
-0.121x |
|
SDI Group plc
LSE:SDI
|
0.048x |
|
LUNGLIFE AI INC. DL-0001
F:9H4
|
N/A |
|
Anpario Plc
LSE:ANP
|
0.112x |
Annual Cash Flow Conversion Efficiency for ALPHAHELIX MOL.DIAGN. SK1 (2022–2025)
The table below shows the annual cash flow conversion efficiency of ALPHAHELIX MOL.DIAGN. SK1 from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see ALPHAHELIX MOL.DIAGN. SK1 stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €637.00K ≈ $744.72K |
€820.00K ≈ $958.67K |
1.287x | +219.69% |
| 2024-12-31 | €4.18 Million ≈ $4.88 Million |
€-4.49 Million ≈ $-5.25 Million |
-1.076x | -105.67% |
| 2023-12-31 | €10.41 Million ≈ $12.18 Million |
€-5.45 Million ≈ $-6.37 Million |
-0.523x | -462.81% |
| 2022-12-31 | €19.89 Million ≈ $23.25 Million |
€2.87 Million ≈ $3.35 Million |
0.144x | -- |
About ALPHAHELIX MOL.DIAGN. SK1
Level Bio AB (publ) manufactures and distributes cutting-edge and diagnostic solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to … Read more